Careium AB (Publ) (STO:CARE)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 574.10M |
| Revenue (ttm) | 866.30M |
| Net Income (ttm) | 33.00M |
| Shares Out | 24.33M |
| EPS (ttm) | 1.35 |
| PE Ratio | 17.48 |
| Forward PE | 11.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,312 |
| Average Volume | 50,186 |
| Open | 23.40 |
| Previous Close | 23.20 |
| Day's Range | 23.10 - 23.60 |
| 52-Week Range | 18.50 - 33.10 |
| Beta | 0.60 |
| RSI | 68.64 |
| Earnings Date | Apr 23, 2026 |
About Careium AB (Publ)
Careium AB (Publ) provides technology-enabled care services in Sweden, Norway, the United Kingdom, the Netherlands, Germany, and France. The company offers Eliza and Eliza S+ personal alarm products; Enzo, a personal alarm trigger product; Careium 500, Careium 450, and Abby GPS personal alarms; Amy, a GPS alarm watch; and Motion 9200 wireless motion sensors. It also provides Ellis, a personal alarm pendant; PikoButton, an alarm button for users with reduced motor skills; pull cord alarm products; magic stick bed and chair sensors; environmental... [Read more]
Financial Performance
In 2025, Careium AB (Publ)'s revenue was 854.10 million, a decrease of -1.91% compared to the previous year's 870.70 million. Earnings were 32.50 million, a decrease of -44.35%.
Financial StatementsNews
Careium AB (Publ) Earnings Call Transcript: Q2 2025
Q2 2025 saw an 11.9% sales decline, but gross margin improved and key contracts were won in France and the UK. Guidance for a stronger H2 is maintained, with optimism for improved sales and profitability as major contracts ramp up.
Careium AB (Publ) Earnings Call Transcript: Q1 2025
Q1 saw growth in all markets except Sweden, with strong margin performance aided by a UK one-time effect. Guidance for 2025 is maintained, focusing on B2C, assisted living, and acquisitions, despite ongoing Swedish market headwinds.
Careium AB (Publ) Earnings Call Transcript: Q4 2024
Carium delivered strong Q4 and full-year profitability, with robust growth in the UK and other European markets, despite Swedish market delays. 2025 guidance anticipates higher sales and profitability, with a focus on new markets and acquisitions.
Careium AB (Publ) Transcript: ABGSC Investor Days
Europe’s aging population is driving rapid growth in technology-enabled care, with the company focusing on organic expansion in major markets, product innovation, and selective acquisitions. Recurring revenue and a broad, quality-focused portfolio underpin its competitive edge.
Careium AB (Publ) Earnings Call Transcript: Q3 2024
Q3 2024 saw sales decline due to infrastructure delays, but profitability remained strong and new innovations like the Eye Care Center and Spanish market entry support future growth. Full-year guidance is maintained, with normalization expected as transitions resolve.
Careium AB (Publ) Earnings Call Transcript: Q2 2024
Q2 2024 saw stable growth and improved profitability despite market slowdowns in the UK and Sweden, with strong gains in other European markets and the launch of the Resilient SIM. Full-year guidance is maintained, and further R&D investment is prioritized.